Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Pulmatrix, Inc. on May 25, 2018. The filing addresses Item 8.01 (Other Events) regarding the Company's Stockholders' Equity as of March 31, 2018, adjusted to reflect the closing of a public offering that occurred on April 3 and April 4, 2018.
Key Financial Metrics
The filing focuses on equity capitalization rather than operational performance metrics such as revenue, profit, or cash flow, which are not provided in this document.
- Actual Stockholders' Equity (March 31, 2018): $7,528,000
- Pro-Forma Stockholders' Equity (March 31, 2018): Approximately $22,001,000
- Public Offering Details: Issuance of 16,810,000 Common Units and 7,840,000 Pre-Funded Units.
- Capital Structure Impact: Common shares outstanding increased from 22,280,160 (actual) to 39,090,160 (pro-forma).
- Accumulated Deficit: $179,223,000 (unchanged in pro-forma adjustment).
Material Changes
The primary material change is the significant increase in Stockholders' Equity resulting from the Public Offering. The pro-forma adjustment added approximately $14,473,000 to the equity balance, raising it from $7,528,000 to $22,001,000. This increase was necessary to satisfy the stockholders' equity requirement under Rule 5450(b)(1)(A) of the NASDAQ Listing Rules.
Outlook, Risks, and Management Commentary
Management states that the Company believes it has satisfied the NASDAQ stockholders' equity requirement as of the filing date. However, the Company notes it will continue to monitor ongoing compliance. A specific risk is identified: if the Company does not evidence compliance at the time of its next periodic report, it may be subject to delisting. The pro-forma financial data presented has not been reviewed by independent auditors.
Investor Verification Checklist
- Verify the final closing details and net proceeds of the Public Offering described in the filing.
- Confirm the Company's continued compliance with NASDAQ listing requirements in subsequent periodic reports to avoid delisting.
- Review the terms of the Series A and Series B Warrants included in the Common Units and Pre-Funded Units.
- Check for any independent auditor review of the pro-forma equity figures in future filings.